['type 2 diabetes']
['isis-gcgrrx', 'placebo']

        Inclusion Criteria:

          -  Male or female, age 18 to 75

          -  BMI ≥ 25.0 kg/m2 < 36.0 kg/m2

          -  HbA1c ≥ 7.5% and ≤ 10.5%

          -  Type 2 Diabetes Mellitus and on stable dose of Metformin. Patients must have been on a
             stable dose of oral metformin (at least 1000 mg/day) for a minimum of 3 months prior
             to screening evaluation and will be required to continue their stable dose of
             metformin throughout the study. Patients on a stable dose of metformin plus a
             sulfonylurea (SU) or metformin plus a dipeptidyl peptidase-IV (DPPIV) inhibitor for a
             minimum of 3 months prior to Screening evaluation may be allowed

          -  Agree to conduct home-based (fasted) blood glucose testing as directed

        Exclusion Criteria:

          -  Clinically significant abnormalities in medical history or physical exam

          -  Show evidence of uncorrected hypothyroidism or hyperthyroidism

          -  History of liver transplantation or renal dialysis

          -  History of liver disease

          -  History of greater than 3 episodes of severe hypoglycemia within 6 months of screening

          -  Treatment with any other antidiabetic drug(s) other than metformin, SU or DPPIV within
             3 months of screening

          -  History of diabetic ketoacidosis

          -  Any other significant illness or condition that may interfere with the patient
             participating or completing the study

          -  Inability or unwillingness to comply with protocol or study procedures -
      